Edward C. Chao, DO

AI in diabetes care is becoming more popular with various potential benefits for patients and clinicians as well as important challenges to keep in mind, according to a conversation between two diabetes experts.

ORLANDO — In this video exclusive, James R. Gavin III, MD, PhD, Healio | Endocrine Today co-editor, talks with Edward C. Chao, DO, about the importance of not worsening disparities with the implementation of AI in diabetes care.

ORLANDO — In this video exclusive, James R. Gavin III, MD, PhD, Healio | Endocrine Today co-editor, talks with Edward C. Chao, DO, about important considerations for using AI in clinical practice.

ORLANDO — In this video exclusive, James R. Gavin III, MD, PhD, Healio | Endocrine Today co-editor, talks with Edward C. Chao, DO, about the benefits and challenges of using AI in diabetes care.

Could a delivery device for diabetes medication be the size of a matchstick? An investigational mini-pump may be one of the next potentially paradigm-changing developments in diabetes treatment. Two phase 3 studies presented at the recent 75th Scientific Sessions of the American Diabetes Association provided a glimpse of a possible future.

Most osteoporosis medications are antiresorptive — they prevent or decrease bone loss, but are not anabolic or bone-forming. A humanized monoclonal antibody, romosozumab, appears promising for reversing osteoporosis. This drug targets a glycoprotein termed sclerostin. Secreted by osteocytes, sclerostin interferes with osteoblast proliferation, thus resulting in decreased bone formation.

We have recently made great strides in the treatment of diabetes; for example, 12 classes of oral therapeutic agents are now available.

A drug holiday is used for multiple medications, from those used to treat HIV to osteoporosis. The word “holiday” can be misleading in osteoporosis therapy, as it connotes that the break in treatment is transient.

I recently saw a 56-year-old gentleman with type 2 diabetes, who sheepishly admitted to running out of his diabetes medications. When I’d asked whether he’d brought his logbook and glucometer, he even more sheepishly replied, “Doc, I’m sorry, but I don’t know where my meter is. I haven’t checked in like 3, maybe 6, months.” Does this scenario sound familiar to you?

Have you ever asked, “Why, in 2013, are our main tools for recruiting for clinical studies fliers and ads in local newspapers?” Finding volunteers has often been quite challenging — are there other ways? There are, and this month, I’ll explore two instances and their potential impact.